Words of wisdom. Re: Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Stillebroer AB, Mulders PFA, Boerman DC, Oyen WJG, Oosterwijk. E Eur Urol. In press. DOI: 10.1016/j.eururo.2010.03.015.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 20845535.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The authors analysed the potential use and limitations of carbonic anhydrase IX (CAIX) antigen as a marker with diagnostic and prognostic value in cases of clear-cell renal cell carcinoma (ccRCC). The study reports that >95% of ccRCCs show high and homogeneous levels of CAIX expression by reverse transcription-polymerase chain reaction and immunohistochemistry. Monoclonal antibody (MAb) G250 has a high affinity for the CAIX antigen. Using MAb G250 in iodine 131-G250 radioimmunoscintigraphy (RIS) and fluorodeoxyglucose F 18 positron emission tomography (PET) can detect primary ccRCC and metastatic sites through the affinity with CAIX antigen. CAIX expression in ccRCC is also presented as a significant and independent adverse predictor of survival. Finally, CAIX has a potential role as a predictor of response to immunotherapy. Seventy-eight percent of renal cell carcinomas(RCCs) responding to interleukin-2 therapy showed high CAIX-expressing primary tumours. Similarly, CAIX expression was associated with a significantly higher treatment response rate in patients with metastatic RCC who received sorafenib.